Axsome Therapeutics vs Corcept Therapeutics
Corcept Therapeutics is the larger business, with $761m of revenue in fiscal 2025 against $638m for Axsome Therapeutics (1.2 times as much). Axsome Therapeutics grew faster (65.5% against 12.8%). Corcept Therapeutics kept more of each dollar of sales as profit: a net margin of 13.1% against -28.7%. Corcept Therapeutics carries less debt relative to equity (0.0% against 212.6%).
| Latest fiscal year | Axsome TherapeuticsAXSM, 2025 | Corcept TherapeuticsCORT, 2025 |
|---|---|---|
| Revenue | $638m | $761m |
| Revenue growth | 65.5% | 12.8% |
| Net income | −$183m | $99.7m |
| Operating margin | -26.1% | 5.9% |
| Net margin | -28.7% | 13.1% |
| Return on equity | — | 15.0% |
| Free cash flow | −$93.9m | $142m |
| Cash | $323m | $120m |
| Total debt | $188m | $0 |
| Debt to equity | 212.6% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $173m |
| Employees | — | 730 |
| Market value | $7.38bn | $8.82bn |
| Price vs our value range | — | Above our value range |
| Moat score | — | 75 (Strong) |
| Insider trades, 12 months | 0 buys, 33 sales | 2 buys, 111 sales |